Reported Sunday, Molecular Partners Presents Updated MP0533 Phase 1/2a AML Data At ASH Annual Meeting With Clinical Benefit And Acceptable Safety Across Dosing Regimens

Benzinga · 2d ago
  • Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens
  • Accelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure
  • Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533